Caplyta shortage update: What patients need to know in 2026

Caplyta Shortage Update: What Patients Need to Know in 2026

If you've had trouble filling your Caplyta (Lumateperone) prescription recently, you might be wondering: is there a Caplyta shortage? It's a valid question — and you deserve a clear answer.

Here's what's happening with Caplyta availability in 2026, why you might be having trouble finding it, and what you can do right now.

Is Caplyta Still in Shortage?

As of early 2026, Caplyta is not listed on the FDA or ASHP drug shortage databases. That means there is no official, nationwide shortage of the medication. The manufacturer — Intra-Cellular Therapies, now part of Johnson & Johnson — continues to produce and distribute Caplyta.

However, many patients are still reporting difficulty finding it at their local pharmacy. This disconnect between "no official shortage" and "I can't find it anywhere" is common with expensive brand-name specialty medications.

Why Is Caplyta Hard to Find?

Even without a formal shortage, several factors make Caplyta difficult to locate:

• Brand-only status: There is no generic version of Caplyta. Every capsule comes from a single manufacturer, which limits overall supply flexibility.
• Growing demand: The FDA approved Caplyta for major depressive disorder (MDD) as an adjunctive therapy in November 2025. This third indication significantly expanded the patient population, driving up demand.
• High cost: At $1,650 to $1,800 per month without insurance, many pharmacies are hesitant to keep large quantities in stock. If a pharmacy doesn't have regular Caplyta customers, they may not order it at all.
• Insurance barriers: Prior authorization and step therapy requirements create delays that can make it seem like the drug is unavailable when it's really an insurance issue.

For a more detailed explanation, read our article on why Caplyta is so hard to find.

How Much Does Caplyta Cost in 2026?

The cost of Caplyta depends on your insurance coverage:

• Without insurance: $1,650 to $1,800 per month for 30 capsules of 42 mg
• With the manufacturer savings card: As low as $15 per fill for eligible commercially insured patients (maximum benefit of $600 per fill)
• With commercial insurance: Copays vary widely, typically $30 to $100+ depending on your plan's formulary tier
• With discount cards (GoodRx, SingleCare): Around $1,650 per month — helpful if you have no insurance, but still expensive

For more ways to reduce your costs, see our complete guide on how to save money on Caplyta.

40,089+ patients found their medications in stock

40K+

Find Caplyta In Stock Today →

New Options in 2026

The landscape for Caplyta and similar medications is evolving:

• Expanded MDD approval: With the November 2025 MDD approval, more doctors — including primary care physicians — may now prescribe Caplyta, which could improve familiarity and stocking at pharmacies.
• Patient support programs: The Caplyta withMe program offers savings cards, free voucher programs, and help with prior authorizations.
• Alternative medications: If Caplyta remains difficult to access, options like Latuda, Vraylar, Rexulti, and Seroquel may be worth discussing with your doctor.

How to Find Caplyta in Stock

Here are the most effective steps you can take right now:

1. Search on Medfinder: Use Medfinder.com to check which pharmacies near you have Caplyta in stock. It shows real-time availability.
2. Call independent pharmacies: Smaller pharmacies can often order Caplyta within 1-2 business days.
3. Request your refill early: Give your pharmacy 5-7 days of lead time so they can order it if needed.
4. Ask about mail-order options: Some insurance plans offer mail-order pharmacy services with better specialty drug availability.

For more tips, read our detailed guide on how to find Caplyta in stock near you.

Skip the calls, skip the stress.

Find Caplyta In Stock Today →

50K+

Medications
Found

99%

Success
Rate

6+

Hours saved
on average

Final Thoughts

Caplyta is not in a formal shortage in 2026, but real-world availability challenges continue for many patients. The combination of brand-only status, increased demand from the new MDD approval, high cost, and insurance barriers means finding Caplyta requires some extra effort.

Start with Medfinder to check availability, explore savings options, and work closely with your doctor and pharmacist. You have more options than you might think.